• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

by Elena Iemma | May 1, 2023

Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune Cell-Engagers 
Poster: Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Poster: Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Elena Iemma | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H    
Vaccine Optimization by Identification, Characterization, and Downselection of Human T Cell Epitopes from Plasmodium falciparum Circumsporozoite Protein.

Vaccine Optimization by Identification, Characterization, and Downselection of Human T Cell Epitopes from Plasmodium falciparum Circumsporozoite Protein.

by Annie De Groot | Nov 23, 2019

Vaccine Optimization by Identification, Characterization, and Downselection of Human T Cell Epitopes from Plasmodium falciparum Circumsporozoite Protein.
Modulation of B. pseudomallei Immune Responses by Human-like T Cell Epitopes

Modulation of B. pseudomallei Immune Responses by Human-like T Cell Epitopes

by Annie De Groot | Nov 20, 2019

Modulation of B. pseudomallei Immune Responses by Human-like T Cell Epitopes
The iVAX Toolkit: An in silico platform for epitope discovery with applications to human and animal vaccine design

The iVAX Toolkit: An in silico platform for epitope discovery with applications to human and animal vaccine design

by Annie De Groot | Oct 23, 2019

EpiVax_ISV_iVAX_23Oct19
« Older Entries

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.